We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
Turnover
15.59%
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
+2.9%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.56B
AUM Growth
-$71.2M
(-2.7%)
Cap. Flow
-$99.6M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
27
Reduced
32
Closed
20
Avg Time Held
4.2
years
Top 10 Avg Time Held
3.2
years
Top 20 Avg Time Held
4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$20M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$14.2M |
| 3 |
Amgen
AMGN
|
+$14.1M |
| 4 |
Insulet
PODD
|
+$13.3M |
| 5 |
Baxter International
BAX
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$31.7M |
| 2 |
Cigna
CI
|
+$22.5M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$22.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$13.8M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.28% |
| 2 | Real Estate | 2.09% |
| 3 | Miscellaneous | 1.37% |
| 4 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
Altimmune
ALT
$453M
| $265K | 0.01% |
75,000
| – | – |
2023 Q1
1 quarter
|
|
152
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $203K | 0.01% |
43,394
| – | – |
2021 Q3
7 quarters
|
|
153
Codexis
CDXS
$142M
| $194K | 0.01% |
69,125
| – | – |
2022 Q3
3 quarters
|
|
|
HARP
154
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $185K | 0.01% |
25,991
| – | – |
2022 Q1
5 quarters
|
|
155
Precision BioSciences
DTIL
$168M
| $118K | ﹤0.01% |
7,484
| – | – |
2021 Q1
9 quarters
|
|
|
SPPI
156
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $110K | ﹤0.01% |
114,670
| – | – |
2018 Q3
19 quarters
|
|
157
Adicet Bio
ACET
$47.6M
| $98K | ﹤0.01% |
2,521
| – | – |
2021 Q4
6 quarters
|
|
158
Praxis Precision Medicines
PRAX
$6.99B
| $86.3K | ﹤0.01% |
5,000
| – | – |
2020 Q4
10 quarters
|
|
159
Oruka Therapeutics
ORKA
$4.98B
| $65.9K | ﹤0.01% |
2,705
| – | – |
2015 Q3
31 quarters
|
|
160
Nkarta
NKTX
$143M
| $63.5K | ﹤0.01% |
28,988
| – | – |
2021 Q1
9 quarters
|
|
|
MNK
161
DELISTED
Mallinckrodt plc
MNK
| $41.4K | ﹤0.01% |
35,048
| – | – |
2022 Q4
2 quarters
|
|
162
Corbus Pharmaceuticals
CRBP
$83.7M
| $40.3K | ﹤0.01% |
5,143
| – | – |
2020 Q2
12 quarters
|
|
|
YARW
163
Yarrow Bioscience
YARW
$161M
| $30.5K | ﹤0.01% |
150
| – | – |
2020 Q1
13 quarters
|
|
164
NexGel
NXGL
$2.04M
| $10.7K | ﹤0.01% |
212
| – | – |
2022 Q1
5 quarters
|
|
|
BLCM
165
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $2.22K | ﹤0.01% |
6,000
| – | – |
2014 Q4
34 quarters
|
|
166
Addus HomeCare
ADUS
$2.2B
| – | – |
-42,380
| Closed | -$4.52M | – |
|
167
Align Technology
ALGN
$10.3B
| – | – |
-6,925
| Closed | -$2.31M | – |
|
168
DELISTED
Amedisys
AMED
| – | – |
-68,949
| Closed | -$5.07M | – |
|
169
Arrowhead Research
ARWR
$8.36B
| – | – |
-100,422
| Closed | -$2.55M | – |
|
170
Biohaven
BHVN
$1.74B
| – | – |
-35,087
| Closed | -$479K | – |
|
171
DELISTED
Blueprint Medicines
BPMC
| – | – |
-67,710
| Closed | -$3.05M | – |
|
172
Kura Oncology
KURA
$872M
| – | – |
-283,281
| Closed | -$3.46M | – |
|
173
Labcorp
LH
$26.1B
| – | – |
-46,609
| Closed | -$9.19M | – |
|
174
Lantheus
LNTH
$6.53B
| – | – |
-79,495
| Closed | -$6.56M | – |
|
175
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-6,495
| Closed | -$667K | – |
|
Similar funds
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Tekla Capital Management held 186 positions worth $2.56B, down 2.7% from $2.63B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management withdrew a net $99.6M in Q2 2023, closing 20 positions and reducing 32 holdings. Its most notable exit was Travere Therapeutics, an estimated $9.41M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Real Estate and Miscellaneous.
Against the trend, Tekla Capital Management opened a new position in Insulet worth $12.6M.
- Tekla Capital Management's largest Q2 2023 buy was Insulet: 43,847 shares worth $12.6M.
- Tekla Capital Management added most to Merck in Q2 2023, an estimated $20M increase.
- Tekla Capital Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $31.7M.
- Tekla Capital Management fully exited Travere Therapeutics in Q2 2023, selling an estimated $9.41M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.56B portfolio in Q2 2023.
- Tekla Capital Management opened 9 new positions and closed 20 in Q2 2023.
- Tekla Capital Management's portfolio value fell 2.7% quarter-over-quarter to $2.56B.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.